[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2260875T3 - Folatreceptor-targetede billeddannelsesmidler - Google Patents

Folatreceptor-targetede billeddannelsesmidler

Info

Publication number
DK2260875T3
DK2260875T3 DK10179508.6T DK10179508T DK2260875T3 DK 2260875 T3 DK2260875 T3 DK 2260875T3 DK 10179508 T DK10179508 T DK 10179508T DK 2260875 T3 DK2260875 T3 DK 2260875T3
Authority
DK
Denmark
Prior art keywords
imaging agents
folate receptor
targeted imaging
targeted
compound
Prior art date
Application number
DK10179508.6T
Other languages
English (en)
Inventor
Matthew A Parker
Christopher Paul Leamon
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Application granted granted Critical
Publication of DK2260875T3 publication Critical patent/DK2260875T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
DK10179508.6T 2002-05-06 2003-05-06 Folatreceptor-targetede billeddannelsesmidler DK2260875T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37857102P 2002-05-06 2002-05-06
EP09171503.7A EP2151250B1 (en) 2002-05-06 2003-05-06 Vitamin-Targeted imaging agents

Publications (1)

Publication Number Publication Date
DK2260875T3 true DK2260875T3 (da) 2014-06-30

Family

ID=29401611

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10179508.6T DK2260875T3 (da) 2002-05-06 2003-05-06 Folatreceptor-targetede billeddannelsesmidler
DK09171503.7T DK2151250T3 (da) 2002-05-06 2003-05-06 Vitamin-targetede billeddannelsesmidler
DK10179448.5T DK2258401T3 (da) 2002-05-06 2003-05-06 Folat-receptor targetede billeddannelsesmidler

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK09171503.7T DK2151250T3 (da) 2002-05-06 2003-05-06 Vitamin-targetede billeddannelsesmidler
DK10179448.5T DK2258401T3 (da) 2002-05-06 2003-05-06 Folat-receptor targetede billeddannelsesmidler

Country Status (19)

Country Link
US (5) US7128893B2 (da)
EP (4) EP1501551B1 (da)
JP (1) JP4801348B2 (da)
KR (1) KR100978418B1 (da)
CN (2) CN100528241C (da)
AT (1) ATE448799T1 (da)
AU (1) AU2003239383C1 (da)
CA (1) CA2484345C (da)
CY (1) CY1114733T1 (da)
DE (1) DE60330135D1 (da)
DK (3) DK2260875T3 (da)
ES (4) ES2438008T3 (da)
HK (1) HK1141440A1 (da)
IL (1) IL164811A (da)
NZ (1) NZ536467A (da)
PT (2) PT2151250E (da)
SI (2) SI2151250T1 (da)
WO (1) WO2003092742A1 (da)
ZA (1) ZA200408664B (da)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
CN101979095A (zh) 2001-05-02 2011-02-23 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
DK2260875T3 (da) * 2002-05-06 2014-06-30 Endocyte Inc Folatreceptor-targetede billeddannelsesmidler
EP1504010B1 (en) * 2002-05-15 2009-03-25 Endocyte, Inc. Vitamin-mitomycin conjugates
EP1592457B1 (en) 2003-01-27 2012-07-25 Endocyte, Inc. Folate-vinblastine conjugate as medicament
US20060204565A1 (en) * 2003-05-06 2006-09-14 Low Philip S Conjugates and use thereof
WO2004110250A2 (en) 2003-05-30 2004-12-23 Purdue Research Foundation Diagnostic method for atherosclerosis
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP2008519859A (ja) * 2004-11-10 2008-06-12 ユニバーシティー オブ サウス フロリダ 標的化した薬物送達のための白金錯体
CA2592302C (en) * 2004-12-23 2013-10-29 Purdue Research Foundation Positron emission tomography imaging method
EP1863816B1 (en) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
WO2007006041A2 (en) * 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
EP2382995A3 (en) 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
CN103893778A (zh) 2005-08-19 2014-07-02 恩多塞特公司 多药物配体缀合物
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US8685752B2 (en) * 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
CA2677792C (en) * 2007-02-07 2015-04-14 Purdue Research Foundation Positron emission tomography imaging method
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
US9216228B2 (en) 2007-02-16 2015-12-22 KTB Tumorforschungsgesellschaft MBM Receptor and antigen targeted prodrug
CN101678124A (zh) 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
WO2008125613A1 (en) 2007-04-11 2008-10-23 Merck Eprova Ag 18f-labelled folates
CN101646672B (zh) * 2007-04-11 2015-08-19 默克和西伊公司 用于诊断成像和放射治疗的叶酸轭合物和相应的金属螯合物络合物
CA2688308A1 (en) * 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CN102014956B (zh) * 2007-08-17 2015-06-03 普渡研究基金会 Psma结合配体-接头缀合物及其使用方法
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
WO2009065002A1 (en) * 2007-11-15 2009-05-22 Endocyte, Inc. Method of administering conjugates
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US8426398B2 (en) 2009-01-13 2013-04-23 Emory University Conjugates of noscapine and folic acid and their use in treating cancer
CA2753975C (en) 2009-03-02 2017-09-26 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
EP2403412A4 (en) * 2009-03-05 2013-08-07 Purdue Research Foundation PROCESS FOR EARLY IMAGING OF ATHEROSCLEROSIS
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
CN102834526B (zh) 2010-04-05 2015-12-02 普罗格诺西斯生物科学公司 空间编码的生物学测定
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
US20120231069A1 (en) 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
JP6152104B2 (ja) 2011-08-17 2017-06-21 メルク・アンド・コンパニー アルブミン結合実体のホラートコンジュゲート
EP2800586A1 (en) 2012-01-03 2014-11-12 Invictus Oncology Pvt. Ltd. Ligand-targeted molecules and methods thereof
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
CA2880001A1 (en) * 2012-07-25 2014-01-30 Emory University Imaging and therapeutic methods for treating parathyroid tumors
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
EP3901280A1 (en) 2012-10-17 2021-10-27 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
KR101551232B1 (ko) 2012-10-26 2015-09-10 한국원자력연구원 Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물
CN108042811A (zh) 2012-11-15 2018-05-18 恩多塞特公司 用于治疗由psma表达细胞引起的疾病的共轭物
WO2014150943A1 (en) * 2013-03-15 2014-09-25 Purdue Research Foundation Asthma imaging and therapy
EP3013984B1 (en) 2013-06-25 2023-03-22 Prognosys Biosciences, Inc. Methods for determining spatial patterns of biological targets in a sample
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
CN108514646B (zh) * 2013-11-14 2021-07-16 恩多塞特公司 用于正电子发射断层术的化合物
US11162937B2 (en) 2013-11-19 2021-11-02 Purdue Research Foundation Patient selection method for inflammation
JP2017513931A (ja) 2014-04-03 2017-06-01 インビクタス オンコロジー ピーヴィティー．リミテッド 超分子コンビナトリアル治療薬
EP3160514B1 (en) * 2014-06-27 2024-07-31 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
US20160166679A1 (en) * 2014-12-12 2016-06-16 Purdue Research Foundation Method of treatment using folate conjugates and tyrosine kinase inhibitors
JP2018504380A (ja) 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒｅｖｅｒｓｉｒ（商標）化合物
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016111834A1 (en) 2015-01-09 2016-07-14 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
EP4151748B1 (en) 2015-04-10 2023-12-20 10x Genomics Sweden AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
EP3324980B1 (en) 2015-07-17 2021-11-10 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
EP3334466B1 (en) * 2015-08-14 2020-05-13 Endocyte, Inc. Method of imaging with a chelating compound
WO2017096158A1 (en) 2015-12-04 2017-06-08 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
JP2019515880A (ja) 2016-03-16 2019-06-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 炭酸無水酵素ｉｘ阻害剤抱合体およびその使用
AU2017234676A1 (en) * 2016-03-16 2018-09-20 Purdue Research Foundation Carbonic anhydrase IX targeting agents and methods
US20170296679A1 (en) * 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
CN111225688A (zh) 2017-08-22 2020-06-02 普渡研究基金会 靶向碳酸酐酶阳性癌症的基于fbsa的治疗和放射性成像缀合物
TW202016301A (zh) 2018-05-07 2020-05-01 美商阿里拉姆製藥股份有限公司 肝外遞送技術
WO2020069055A1 (en) 2018-09-28 2020-04-02 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
JP2022532652A (ja) 2019-05-17 2022-07-15 アルニラム ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの経口送達
WO2021086982A2 (en) 2019-10-28 2021-05-06 Beckman Coulter, Inc. Compounds for the identification of microbial classes and uses thereof
WO2021092145A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
AU2020378414A1 (en) 2019-11-06 2022-05-26 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
EP4421186A3 (en) 2020-06-08 2024-09-18 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
WO2022011214A1 (en) 2020-07-10 2022-01-13 Alnylam Pharmaceuticals, Inc. Circular sirnas
CN116916968A (zh) 2020-10-30 2023-10-20 托德·斯皮尔 基于寡核苷酸的治疗剂及其用途
WO2022147223A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
JP2024501857A (ja) 2020-12-31 2024-01-16 アルナイラム ファーマシューティカルズ， インコーポレイテッド 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
US20240165250A1 (en) * 2021-01-08 2024-05-23 Lycia Therapeutics, Inc. Bifunctional Folate Receptor Binding Compounds
EP4347879A1 (en) 2021-06-03 2024-04-10 10X Genomics, Inc. Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
EP4367237A2 (en) 2021-07-09 2024-05-15 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
JP2024526890A (ja) 2021-07-21 2024-07-19 アルナイラム ファーマシューティカルズ， インコーポレイテッド 代謝障害関連標的遺伝子ｉｒｎａ組成物およびその使用方法
CA3234887A1 (en) 2021-10-15 2023-04-20 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
WO2023220744A2 (en) 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024073732A1 (en) 2022-09-30 2024-04-04 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816110A (en) 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US5140104A (en) 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US5175343A (en) * 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
NZ217821A (en) 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
DE69230525T2 (de) 1991-02-08 2000-06-21 Diatide, Inc. Technetium-99m markierte Polypeptide zur Bildformung
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US6022966A (en) 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
DE4310999C2 (de) * 1993-03-31 1996-07-18 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ XN¶1¶S¶1¶X' für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4311021A1 (de) * 1993-03-31 1994-10-27 Diagnostikforschung Inst Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel
DE4311023C2 (de) * 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4311022C2 (de) * 1993-03-31 1996-07-11 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4425781A1 (de) * 1994-07-14 1996-01-18 Schering Ag Technetium-Sulfonamid-Komplexe, deren Verwendung, diese enthaltende pharmazeutische Mittel, sowie Verfahren zur Herstellung der Komplexe und Mittel
US6083480A (en) * 1997-05-01 2000-07-04 Diatide, Inc. Calcitonin receptor binding reagents
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6323313B1 (en) * 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
ES2518926T3 (es) * 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
CN101979095A (zh) 2001-05-02 2011-02-23 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
DK2260875T3 (da) 2002-05-06 2014-06-30 Endocyte Inc Folatreceptor-targetede billeddannelsesmidler
EP1592457B1 (en) * 2003-01-27 2012-07-25 Endocyte, Inc. Folate-vinblastine conjugate as medicament
US20060204565A1 (en) * 2003-05-06 2006-09-14 Low Philip S Conjugates and use thereof

Also Published As

Publication number Publication date
EP2151250B1 (en) 2013-10-02
PT2260875E (pt) 2014-06-25
JP4801348B2 (ja) 2011-10-26
AU2003239383B2 (en) 2008-10-16
EP2258401A3 (en) 2011-08-24
ES2500922T3 (es) 2014-10-01
US8313728B2 (en) 2012-11-20
DE60330135D1 (de) 2009-12-31
DK2151250T3 (da) 2013-12-16
CN1662263A (zh) 2005-08-31
CY1114733T1 (el) 2016-12-14
KR20040104686A (ko) 2004-12-10
NZ536467A (en) 2006-11-30
US20140065068A1 (en) 2014-03-06
AU2003239383C1 (en) 2009-03-19
ES2472423T3 (es) 2014-07-01
EP2258401A2 (en) 2010-12-08
ES2336780T3 (es) 2010-04-16
EP1501551B1 (en) 2009-11-18
EP2258401B1 (en) 2014-07-09
EP1501551A1 (en) 2005-02-02
EP2151250A1 (en) 2010-02-10
AU2003239383A1 (en) 2003-11-17
KR100978418B1 (ko) 2010-08-26
EP2260875A3 (en) 2011-08-24
EP2260875A2 (en) 2010-12-15
US20090324499A1 (en) 2009-12-31
CA2484345C (en) 2015-09-29
US20040033195A1 (en) 2004-02-19
DK2258401T3 (da) 2014-10-13
JP2006501149A (ja) 2006-01-12
IL164811A (en) 2012-06-28
US20130237687A1 (en) 2013-09-12
CN101648028A (zh) 2010-02-17
US8865126B2 (en) 2014-10-21
JP4801786B2 (ja) 2011-10-26
WO2003092742A1 (en) 2003-11-13
US7862798B2 (en) 2011-01-04
JP2011012066A (ja) 2011-01-20
ES2438008T3 (es) 2014-01-15
CN101648028B (zh) 2012-11-21
EP1501551A4 (en) 2006-01-11
ZA200408664B (en) 2007-04-25
US8834842B2 (en) 2014-09-16
EP2260875B1 (en) 2014-04-23
US20070031334A1 (en) 2007-02-08
US7128893B2 (en) 2006-10-31
ATE448799T1 (de) 2009-12-15
SI2151250T1 (sl) 2014-02-28
CA2484345A1 (en) 2003-11-13
SI2260875T1 (sl) 2014-07-31
PT2151250E (pt) 2013-12-09
CN100528241C (zh) 2009-08-19
HK1141440A1 (en) 2010-11-12

Similar Documents

Publication Publication Date Title
DK2260875T3 (da) Folatreceptor-targetede billeddannelsesmidler
DK1385514T5 (da) Spiroinden- og spiroindanforbindelser
BR0307924A (pt) N-aril-2-oxazolidinona-5-carboxamidas e seus derivados
CY1113054T1 (el) Παραγωγα διαμινης
ATE302775T1 (de) Carbolinderivate
DK1414828T3 (da) Antitumoranaloger
CY1114284T1 (el) Σουλφονυλοπυρρολες ως hdac αναστολεις
DE60334567D1 (de) Universal-shunt-verschluss
DE60230163D1 (de) Sicherheitsgurt-vorspannvorrichtung
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
DE60110844D1 (de) Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten
ITMI20011306A0 (it) Poliuretani vulcanizzabili
ATE346067T1 (de) Carbolinderivate
NO20010100D0 (no) Beltestyreenhet
MY146098A (en) Oxazole derivatives of tetracyclines
PA8543701A1 (es) Fenil-heterociclil-eteres
BRPI0409143A (pt) n-aril-2-oxazolidinona-5-carboxamidas e seus derivados
BRPI0413744A (pt) n-aril-2-ciano-oxazolidinonas e seus derivados
EE200300573A (et) Fungitsiididena kasutatavad oksasiin(ti)oonühendid
ATE478155T1 (de) Glycopeptidantibiotika
CY1115764T1 (el) Αναστολεις iap
ATE360010T1 (de) Heterocyclische retioidverbindungen
UA4789S (uk) Фурнітура до замка
FI5333U1 (fi) Porakoneen lisälaite
TH60771A (th) ไพร์โรโลควิโนโลนที่เป็นสารต้านไวรัส